



Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

Mototsugu Oya¹ · Shuichi Kaneko² · Tsuneo Imai³ · Toshiaki Tsujino⁴ · Toshiyuki Sunaya⁵ · Yutaka Okayama⁴ 

Published online: 16 September 2023
© The Author(s) 2023

Retraction Note: Cancer Chemotherapy and Pharmacology (2022) 89:761-772
<https://doi.org/10.1007/s00280-022-04428-0>

The Authors have retracted this article. After publication the authors found a flaw in the way the raw data was handled for this study and found that the data analysis was incomplete. The authors re-analysed the data and found that the conclusions initially drawn from the results were no longer supported. The authors, therefore, no longer have confidence in the results presented in this article. All authors agree to this retraction.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00280-022-04428-0>.

✉ Yutaka Okayama
yutaka.okayama@bayer.com

- ¹ Department of Urology, Keio University School of Medicine, Tokyo, Japan
- ² Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan
- ³ National Hospital Organization, Higashi Nagoya National Hospital, Nagoya, Japan
- ⁴ Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., 2-4-9 Umeda, Kita-Ku, Osaka 530-0001, Japan
- ⁵ Product Development, Bayer Yakuhin, Ltd., Osaka, Japan